Jacob 'Jake' Leach, President and Chief Executive Officer at Dexcom, has been named chair of the AdvaMed Diabetes Sector, succeeding Chris Scoggins of Abbott1
Leach became Dexcom's permanent CEO on January 1, 2026, after taking the role early in September 2025 when outgoing CEO Kevin Sayer took a leave of absence2
Leach has spent over 22 years at Dexcom, helping grow the company from 30 employees to more than 10,000 worldwide1
Eric Benjamin, Executive Vice President and Chief Operating Officer at Insulet, will serve as the sector's vice chair1
The AdvaMed Diabetes Sector represents the world's leading companies producing technology across the spectrum of diabetes care and advocates for policies that support 40 million Americans living with diabetes and 115 million Americans living with prediabetes1
Sources:
1. https://www.advamed.org/industry-updates/news/dexcoms-jake-leach-named-chair-of-advameds-diabetes-sector/
2. https://www.drugdeliverybusiness.com/dexcom-jake-leach-chair-advamed-diabetes/